BioSpace News Archive

Drug Development

Huntington’s Disease Continues to Baffle Biopharma

Huntington’s disease might just top the list of intractable neurodegenerative diseases. BioSpace spoke with the field’s foremost experts about the challenges and how to overcome them.

November 16, 2022
·
7 min read
·
Heather McKenzie
Deals

Kriya Adds Redpin’s Chemogenetics Pipeline to Growing Gene Therapy Portfolio (Updated)

In the acquisition, announced Wednesday, Kriya picks up two gene therapy programs focused on epilepsy and trigeminal neuralgia. Financial terms of the deal were not disclosed.

November 16, 2022
·
3 min read
·
Heather McKenzie
Remote Clinical Jobs and How to Get Them

If you’re considering working from home in the life science industry, you might want to apply for remote clinical jobs. Continue reading to discover seven examples of remote clinical jobs and how to get them.

November 16, 2022
·
5 min read
·
Franklin Carpenter
Drug Development

AstraZeneca Launches Phase II Trial of Anti-TIGIT NSCLC Therapy (Updated)

AstraZeneca dosed the first patient in a Phase II portion of an ongoing trial assessing a PD-1/TIGIT bispecific antibody, triggering a $7.5 million milestone payment to partner, Compugen.

November 16, 2022
·
2 min read
·
Alex Keown
BioForest

Sana and BioLife Tout BioForest Region as Best Place to Work

CEOs at Sana Biotechnology and BioLife Solutions explain how being based in the BioForest region helped them be voted one of BioSpace’s best places to work in 2023.

November 16, 2022
·
3 min read
·
Rosemary Scott
Drug Development

Reeling from CKD Flop, Tricida Downsizes by Nearly 60%

Tricida, Inc. is reducing its headcount by around 57% to improve its financial standing after its lead candidate failed in a Phase III trial, the company revealed in its third-quarter financial results.

November 16, 2022
·
2 min read
·
Tristan Manalac
Policy

Ardelyx’s CKD Drug Clears FDA Adcomm Hurdle with 9-4 Vote

Ardelyx has moved one step closer to the possible approval of its experimental chronic kidney disease drug tenapanor following a favorable 9-4 vote from an FDA advisory committee.

November 16, 2022
·
3 min read
·
Alex Keown
Chief Executive Offier, Philipp Mathieu, buys Immunovia warrants

Immunovia AB announces that Philipp Mathieu, CEO of Immunovia, has purchased 150000 warrants of the 2022/2026 scheme for approximately 297 KSEK.

November 16, 2022
·
1 min read
Business

LabGenius Appoints Dr. Leonard Wossnig as Chief Technology Officer

LabGenius, a pioneer in the use of machine learning for antibody-based drug discovery, announced the appointment of Leonard Wossnig Ph.D. as Chief Technology Officer.

November 16, 2022
·
3 min read
Business

Rentschler Biopharma appoints Christiane Bardroff as Chief Operating Officer and Member of the Executive Board

Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, announced the appointment of Christiane Bardroff as Chief Operating Officer, effective December 1, 2022.

November 16, 2022
·
5 min read